To receive the Femtech World newsletter, sign up here.
News
Six in 10 UK teens don’t know when to seek help for menstrual problems- survey
The vast majority of UK teens rate their level of knowledge and understanding of the menstrual cycle as poor
Six in 10 UK teenagers do not know when to seek medical help for menstrual cycle problems, a new survey has found.
Endometriosis UK and Menstrual Cycle Support have released the Teen Menstrual Literacy Survey, revealing that six in 10 British teenagers do not have enough understanding to know when to seek medical help for menstrual cycle problems.
The survey found that 30 per cent of teens did not understand what a period was before they had their first one, with the vast majority rating their level of knowledge of the menstrual cycle as poor.
Additionally, the research showed that more than three in four participants said that their menstrual cycle had a negative impact on their mental health as teenager.
The survey coincides with the Parliamentary launch of the Menstrual Cycle Support for Teens course, which aims to reduce stigma and shame around menstrual health and reverse diagnosis times for conditions, such as endometriosis, premenstrual dysphoric disorder (PMDD) and heavy menstrual bleeding.
The initiative, a partnership between Menstrual Cycle Support and Endometriosis UK, is free to all schools and teens on social prescription.
“Young people have the right to understand what is normal when it comes to their bodies,” said Kate Shepherd Cohen, founder and CEO of Menstrual Cycle Support.
“Menstrual literacy improves confidence to chart our cycles, adapt our lives according to the different phases and, crucially, talk about our cycles with clinicians.”
Emma Cox, CEO of Endometriosis UK, said: “Being ‘too young’ to have endometriosis or menstrual health problems is a myth that must be overcome; without a diagnosis treatment can’t be accessed and diseases may progress.
“The impact of lost education and academic attainment can have a lifelong impact on career and prospects. As well as impacting on physical health, the psychological effect of being told your pain is not real, or not believed, can be significant.
“The Menstrual Cycle Support for Teens course will empower future generations, providing the understanding and language they need to effectively seek help.”
The course is clinically backed, peer-reviewed and evidence-informed. It is available through GP surgeries across the UK on social prescription, though anyone can “self-refer” and access the course on the Menstrual Cycle Support website.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Wellness4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






